← Back to Clinical Trials
Recruiting NCT06266403

NCT06266403 Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06266403
Status Recruiting
Phase
Sponsor Penn State University
Condition Amyotrophic Lateral Sclerosis
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2024-11-05
Primary Completion 2029-02-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Structured Communicative InteractionClear SpeechUnstructured communicative interaction

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2024-11-05 with a primary completion date of 2029-02-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers. The question is, What are the effects of communicative interaction on verbal communication in people with ALS? Participants will read words and sentences while they are in a solo setting and interactive setting.

Eligibility Criteria

Inclusion Criteria: Speakers with amyotrophic lateral sclerosis (ALS) (PALS-people with ALS) * diagnosis of ALS following the revised EL Escorial criteria * no history of other neurological conditions (e.g., stroke) * no cognitive impairment assessed by Telephone Montreal Cognitive Assessment (mini MoCA) * detectable speech disturbance according to the ALS Functional Rating Scale-Revised (ALSFRS-R) * the ability to produce single words * being a native speaker of American English (AE). Age-matched Speakers * passing the remote hearing screening * having no known speech, language, or neurological disorders per self-report * no cognitive impairment assessed by Telephone Montreal Cognitive Assessment (mini MoCA) * being a functionally native monolingual speaker of American English. Unfamiliar Interlocutors * passing the remote hearing screening * having no known speech, language or neurological disorders per self-report * being a native monolingual speaker of American English * having no experience communicating with people with dysarthria * being between the ages of 18 and 40. Exclusion Criteria: * None - if volunteer meets the inclusion criteria, then they will be enrolled

Contact & Investigator

Central Contact

Anne Olmstead, Ph.D.

✉ ajo150@psu.edu

📞 814-867-3373

Principal Investigator

Jimin Lee, PhD

PRINCIPAL INVESTIGATOR

The Pennsylvania State University

Frequently Asked Questions

Who can join the NCT06266403 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06266403 currently recruiting?

Yes, NCT06266403 is actively recruiting participants. Contact the research team at ajo150@psu.edu for enrollment information.

Where is the NCT06266403 trial being conducted?

This trial is being conducted at University Park, United States.

Who is sponsoring the NCT06266403 clinical trial?

NCT06266403 is sponsored by Penn State University. The principal investigator is Jimin Lee, PhD at The Pennsylvania State University. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology